Concord Drugs

BSE: 538965 19 Aug 2025

Healthcare

₹ 49.98

Concord Drugs Limited specializes in Pharmaceuticals within the Healthcare sector.

Concord Drugs

BSE: 538965 19 Aug 2025

Healthcare

₹ 49.98

Concord Drugs Limited specializes in Pharmaceuticals within the Healthcare sector.

Book Value

34.1

Dividend Yield

0.0%

Debt to Equity

0.5

Stock P/E

116.0

Market Cap

50.0 Cr

Concord Drugs - Share Price & Details

Market Cap

₹50.0

High /Low

67.0 / 26.1

Stock P/E

116.0

Book Value

₹34.1

Dividend Yield

0.0

ROCE

5.3

ROE

₹1.0

Face Value

10.0

PEG Ratio

-2.89

EVEBITDA

₹15.4

Debt

17.2

CMP / FCF

76.5

Debt to equity

₹0.5

NP Ann

0.34

High price all time

91.2

Piotroski score

₹6.0

Graham Number

18.2

No. Eq. Shares

1.0

Net CF

₹-0.02

Net profit

0.43

Price to book value

1.47

Interest Coverage

₹1.4

Low price all time

11.7

Industry PE

33.5

Reserves

₹24.1

Free Cash Flow

₹1.39

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
Shyama Computronics and Servic	1.48	0.93	0.67	0.00	5.33	35.5
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
Concord Drugs Limited	7.99	-71.62	7.94	0.08	50.0	116.0
TRANSCHEM LTD.	39.86	7.30	24.24	0.60	49.4	10.9
MEDI-CAPS LTD.	11.60	7.06	8.91	0.57	48.7	97.4

Peer Comparison Chart

About Concord Drugs

Concord Drugs Limited, with Security Code 538965, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Concord Drugs Reports Improved Financial Results, Signaling Positive Growth Trajectory in August 2025

(09 Aug 2025)

Concord Drugs has announced its financial results for the quarter ending June 2025, showing a significant improvement in Profit After Tax,...

Concord Drugs consolidated net profit rises 300.00% in the June 2025 quarter

(09 Aug 2025)

Net profit of Concord Drugs rose 300.00% to Rs 0.12 crore in the quarter ended June 2025 as against Rs 0.03 crore during the previous quarter ended June...

Can Concord Drugs Limited (538965) Maintain Its Valuation - Dynamic investment growth

(06 Aug 2025)

Can Concord Drugs Limited (538965) Maintain Its Valuation ✌️【Trading Ideas】✌️ Real data. Real results. Our top picks deliver massive growth...

Concord Drugs Limited (538965) Expands into New Market - Invest confidently with market-leading analysis

(06 Aug 2025)

Concord Drugs Limited (538965) Expands into New Market ✌️【Stock Trends】✌️ Join thousands of investors using expert insights to grow their...

Concord Drugs Limited (538965) vs yyy - Consistent triple returns

(30 Jul 2025)

Concord Drugs Limited (538965) vs yyy ✌️【Stock Analysis】✌️ Join our community for daily expert insights, live stock indices, futures trends,...

Concord Drugs Limited (538965) vs yyy - Unprecedented market success

(24 Jul 2025)

Concord Drugs Limited (538965) vs yyy ✌️【Market Movement】✌️ Real-time market signals and stock forecasts to support smart investing.

Quarterly Table

Standalone Consolidated

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	13.5	11.5	8.8	7.4	12.6	14.5	6.4	11.8	10.8	0.8
Expenses	12.1	10.8	7.4	5.9	12.1	14.3	5.6	11.0	9.5	7.0
Operating Profit	1.4	0.7	1.4	1.5	0.6	0.2	0.7	0.8	1.3	-6.2
OPM %	10.67%	6.42%	15.91%	20.7%	4.44%	1.29%	11.51%	6.7%	12.2%	-780.35%
Other Income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5
Depreciation	0.4	0.3	0.4	0.4	0.4	0.4	0.3	0.3	0.4	0.4
Profit before tax	0.6	0.0	0.6	0.8	-0.3	-0.6	0.0	0.1	0.5	-7.1
Tax %	-26.3%	305.9%	-22.7%	-30.9%	-6.3%	-38.9%	-55.6%	-27%	-57.4%	0%
Net Profit	0.5	0.1	0.5	0.5	-0.2	-0.4	0.0	0.1	0.2	-7.2
EPS in Rs	0.52	0.07	0.52	0.56	-0.24	-0.35	0.01	0.05	0.22	0

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	12.3	9.0	7.5	12.8	15.6	11.7	12.4	10.8	10.4
Expenses	11.3	7.5	5.9	12.2	15.3	10.9	11.5	9.4	9.3
Operating Profit	1.0	1.5	1.6	0.6	0.3	0.8	0.9	1.4	1.1
OPM %	7.87%	16.24%	21.35%	4.92%	2.23%	7.12%	7.01%	12.9%	10.4%
Other Income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest	0.5	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.6
Depreciation	0.3	0.4	0.4	0.4	0.4	0.3	0.3	0.4	0.4
Profit before tax	0.1	0.6	0.8	-0.3	-0.5	0.0	0.1	0.5	0.1
Tax %	15.6%	-22.8%	-29.6%	-6.2%	-38.2%	-34.1%	-33.3%	-56.9%	0%
Net Profit	0.2	0.5	0.6	-0.2	-0.3	0.0	0.0	0.2	0.0
EPS in Rs	0.18	0.53	0.6	-0.24	-0.34	0.03	0.04	0.23	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	2%
5 Years:	-2%
3 Years:	-6%
TTM:	8%

Compounded Profit Growth
10 Years:	2%
5 Years:	0%
3 Years:	2%
TTM:	-108%

Stock Price CAGR
10 Years:	-7%
5 Years:	15%
3 Years:	6%
1 Year:	-20%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	21%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-104%

Stock Price CAGR
10 Years:	-7%
5 Years:	15%
3 Years:	6%
1 Year:	-20%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Concord Drugs

Concord Drugs

Concord Drugs - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About Concord Drugs

Latest News

Concord Drugs Reports Improved Financial Results, Signaling Positive Growth Trajectory in August 2025

Concord Drugs consolidated net profit rises 300.00% in the June 2025 quarter

Can Concord Drugs Limited (538965) Maintain Its Valuation - Dynamic investment growth

Concord Drugs Limited (538965) Expands into New Market - Invest confidently with market-leading analysis

Concord Drugs Limited (538965) vs yyy - Consistent triple returns

Concord Drugs Limited (538965) vs yyy - Unprecedented market success

Concord Drugs Limited (538965) to Launch New Product Line - Free Bull & Bear Market Updates

Where Could Concord Drugs Limited (538965) Be Headed - Exponential wealth increase

Concord Drugs Limited (538965) Hits 52 Week High - Market-beating returns

Writ cannot be invoked to Challenged NFRA Notices: Telangana HC Dismisses Plea of Statutory Auditors of Concord Drugs [Read Order]

Concord Drugs Limited (538965) Stock Experiences Sudden Dip - Free Market Dynamics Reports

Can Concord Drugs Limited (538965) Maintain Its Valuation - Superior risk-adjusted returns

Concord Drugs Limited (538965) to Launch New Product Line - Free Wealth Planning Blueprint

Concord Drugs Adjusts Valuation Amid Mixed Financial Performance and Market Signals

CONCORD DRUGS Share Price Today Up 20%

Concord Drugs Faces Valuation Shift Amid Mixed Financial Indicators and Market Challenges

Concord Drugs Faces Mixed Technical Trends Amid Declining Financial Performance

Concord Drugs Faces Technical Shift Amidst Declining Performance and Valuation Opportunities

Heranba Industries reports consolidated net loss of Rs 41.49 crore in the March 2025 quarter

Stocks to Watch Today: ITC, Sun Pharma, IndusInd Bank, Honasa Consumer, MTAR Tech, Metro Brands, Power Mech, Bharat Electronics in focus on 23 May

Concord Drugs Adjusts Valuation Amid Mixed Performance and Market Challenges

Concord Drugs Standalone March 2025 Net Sales at Rs 7.96 crore, down 44.95% Y-o-Y

Concord Drugs Reports Mixed Financial Results Amid Sales Decline in May 2025

Concord Drugs reports consolidated net profit of Rs 0.04 crore in the March 2025 quarter

Q4 Results Highlights: GNFC profit rises 65% YoY; JSW Steel beats profit estimates

Camlin Fine Sciences reports consolidated net loss of Rs 0.72 crore in the March 2025 quarter

Q4 Results 2025 Today: Ashok Leyland, BEML, JSW Steel Among 200+ Companies To Declare Earnings On May 23

Q4 Results 2025: Over 700 Companies To Declare Earnings This Week, Full List Here

Q4 results: Bharat Electronics, DLF, IRB Infra, Jupiter Wagons, Indigo, IndusInd Bank, EIH Hotels, Power Grid among 700 companies to announce results this week

Q4 Results Next Week: ITC, Hindalco, Pfizer, Power Grid, IndusInd Bank, RVNL, JSW Steel, And More

Pharmaceutical Pellets Market Sees Rapid Expansion Fueled

Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide

Certain medicines with misleading claims seized in Telangana

Schaeffler India, Blue Star, Concord Biotech: Second-rung stocks outperform large caps; BSE SmallCap index up 1%

Volumes jump at Ramkrishna Forgings Ltd counter

Live market news, research and portfolio

Concord Drugs Standalone December 2024 Net Sales at Rs 10.77 crore, down 14.66% Y-o-Y

Concord Drugs reports consolidated net profit of Rs 0.23 crore in the December 2024 quarter

Concord Drugs Reports Flat Q3 Results for FY 2024-25 Amid Mixed Financial Metrics

Sobha Ltd Slips 2.57%, BSE Realty index Shed 1.84%

Biocon surges after Malaysian facility gets classified as VAI by the US FDA

Q3 Results: TCS, IREDA, DMart, JustDial Among Companies To Announce Earnings This Week

Stocks To Watch: Adani Wilmar, TCS, Tata Elxsi, Mahanagar Gas, IREDA, And Others- News18

Concord Drugs Receives 'Hold' Rating After 64.28% Sales Growth in Q3 2024

MarketsMOJO Downgrades Concord Drugs to 'Sell' Rating Due to Weak Fundamentals

Opinion: A holiday wish: Congress must pass PBM reform

Concord Drugs Receives 'Hold' Rating and Shows Positive Growth, But Long-Term Fundamentals Remain Weak

CONCORD DRUGS Share Price Today Up 9%

Concord Drugs Consolidated September 2024 Net Sales at Rs 12.36 crore, up 64.44% Y-o-Y

Three stocks hit the circuits today: 63 Moons Technologies, Kitex Garments and Akums Drugs & Pharmaceuticals hit the upper circuit

Manchester Felon Arrested On Cocaine, Stolen Van Charges In Concord

Concord Drugs Standalone September 2024 Net Sales at Rs 11.84 crore, up 60.4% Y-o-Y

Concord Man Pleads Guilty To Gun, Drug Charges In U.S. District Court

NBCC, Deepak Nitrite, Eicher Motors, Patel Engineering Among 650+ Companies To Declare Q2 Results Today

650 Companies To Declare Q2 Results, Including Godrej Industries, Eicher Motors, AstraZeneca & Garden Reach Shipbuilders

Pharmaceutical Pellets Market Expected to Reach $4.41 Billion by 2031, Driven by Rising Demand for Chronic ...

New rules for US national security agencies balance AI’s promise with need to protect against risks

Biden, Sanders tout prescription drug cost-savings at NH event

Biden says global leaders are terrified of Trump quietly tell him, ‘He can’t win’

Biden says global leaders are terrified of Trump and quietly tell him, ‘He can’t win’

Massachusetts Woman Arrested On Another Drug Charge: Concord Cop Log

Pharmaceutical Pellets Market Scope and Latest Trends Analysis

Letter: Drugs are on the ballot

Pharmaceutical Pellets Market Advancements Highlighted by Size, Share, Global Analysis And Forecast To 2033

Eli Lilly’s Parenteral Product and Device Manufacturing Facility, Concord, North Carolina, US

Concord man arrested with 100 pounds of meth in van

Pharmaceutical Pellets Market Set for Strong Growth, Projected to Reach $4.41 Billion by 2031

PE firm Quadria Capital set to deploy around $1 billion in Indian market

Mass. Woman Arrested On DUI Charge After Crashing Jeep In Concord

Concord Drugs Consolidated June 2024 Net Sales at Rs 11.69 crore, up 30.19% Y-o-Y

Mass. Teen Arrested On Felony Drug, Alcohol Charges: Concord Cop Log